Nautilus Biotechnology (NAUT) investor relations material

Industry context and challenges

• Genomics has advanced significantly, but protein analysis remains a major bottleneck for drug development and precision medicine, with current technologies providing incomplete and inconsistent results.

• Over 90% of new drug development programs fail, partly due to inadequate protein analysis tools, leading to high costs and limited progress in diseases like Alzheimer's.

• Existing proteomics technologies, such as mass spectrometry and assays from major companies, have not improved significantly in 20 years and lack reproducibility and depth.

Nautilus platform and technology

• Nautilus has developed a disruptive proteomics platform using a novel iterative mapping method, integrating life sciences, engineering, and data science.

• The Voyager instrument, priced around $1 million, is designed for high-throughput, reproducible protein analysis and is expected to enter beta in the second half of the year, with general availability next year.

• Consumables and reagents are expected to generate significant recurring revenue, with projected annual pull-through of $500,000 per customer.

• The platform supports both broad scale proteomics and targeted proteoform assays, with the first tau assay for Alzheimer's in early access and oncology and Parkinson's assays in development.

Market opportunity and commercialization

• The proteomics market is projected to reach $57 billion by 2030, with a 13% CAGR, split between biopharma, academic, and applied research.

• Early access programs are focused on academic and nonprofit research, with broader biopharma adoption expected as more assays become available.

• Material revenue is not expected until general availability of both broad scale and targeted assays, anticipated by mid-next year.